Answers are grounded in this paper and cite their sources.
In elderly patients with de novo Ph+ALL, imatinib induction results in a significantly higher CR rate and lower toxicity than induction chemotherapy. With subsequent combined imatinib and chemotherapy consolidation, this initial benefit does not translate into improved survival compared with chemotherapy induction.
No takes yet. Share an insight, caveat, or question.
Ottmann et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: